Phibro Animal Health Corporation Class A (PAHC)
NASDAQ: PAHCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PAHC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.35B
- P/E (TTM)
- 13.26
- Forward P/E
- 8.58
- EPS (TTM)
- $2.51
- Dividend yield
- 1.44% ($0.48)
- Ex-dividend date
- Nov 25, 2026
- 52-week range
- 28.25 – 60.08
- Day range
- 33.27 – 34.54
- Volume / Avg
- 155.54K / 228.99K
- Beta
- —
- Shares outstanding
- 21.11M
52-week range
PAHC stock today
Shares of Phibro Animal Health (PAHC) finished lower on Nov 20 at $33.29, a drop of 2.32% or $0.79 per share, versus the S&P 500's 3.70% decline. At this level, PAHC sits near the bottom of its 52-week range of $28.25 to $60.08: 44.6% below the high, set on Apr 13, 2026 and 17.8% above the low. PAHC is down 10.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.0%.
Phibro Animal Health trades at 13.3x its trailing twelve-month earnings per share of $2.51. Its forward P/E of 8.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. To receive the next $0.12 dividend, investors must own shares before the Nov 25 ex-dividend date.
Summary generated from market data by MetaCap's automated system. Methodology
About Phibro Animal Health
Company profilePhibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Daniel M. Bendheim J.D.
- Headquarters
- Teaneck, NJ
- Employees
- 2,605
- IPO year
- 2014
- Website
- pahc.com
Financial highlights
Full financialsIn fiscal 2026, Phibro Animal Health generated $1.52 billion in revenue, up 17.1% from fiscal 2025, its 6th consecutive year of revenue growth. Net income was $99.7 million (+106.6% year over year), for a net margin of 6.6% versus a median of 3.7% in the prior 5 years. Gross margin was 33.8% (up from 30.9%) and operating margin 12.8%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.52B | $1.30B | $1.02B | $977.89M | $942.26M |
| Growth | +17.12% | +27.37% | +4.07% | +3.78% | +13.07% |
| Net income | $99.72M | $48.26M | $2.42M | $32.61M | $49.17M |
| EPS (diluted) | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 |
Analyst forecast
ForecastConsensus (3 analysts)
hold
Avg. price target
$47.00+41.18%
- Strong buy 1
- Buy 0
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.72 vs $0.79
- Surprise
- -8.86%
Dividends
Dividend history- Annual dividend
- $0.48
- Dividend yield
- 1.44%
- Last payment
- $0.12
- Ex-dividend date
- Nov 25, 2026
- Pay date
- Dec 16, 2026
PAHC news
All PAHC news- Should You Continue to Hold ALGN Stock in Your Portfolio?NasdaqALGN, IDXX, GMED, PAHC
- Here's Why You Should Retain NVST Stock in Your Portfolio for NowNasdaqNVST, IDXX, GMED, PAHC
- Should You Continue to Retain Bruker Stock in Your Portfolio?NasdaqBRKR, IDXX, GMED, PAHC
- Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?NasdaqLH, IDXX, GMED, PAHC
- Phibro: 3 Key Takeaways for Long-Term InvestorsNasdaqPAHC, BF.A
- Should You Continue to Hold TMO Stock in Your Portfolio?NasdaqTMO, IDXX, GMED, PAHC
- Phibro Animal (PAHC) Q1 2027 Earnings Call TranscriptNasdaq
- Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial GuidanceBusiness Wire
Phibro Animal Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NBTXNanobiotix S.A. ADR | 26.50 | -2.98% | $1.35B | vs PAHC |
| URGNUroGen Pharma Ltd. | 27.65 | -12.86% | $1.36B | vs PAHC |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs PAHC |
| NUVBNuvation Bio Inc. Class A | 3.80 | -0.26% | $1.34B | vs PAHC |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs PAHC |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs PAHC |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs PAHC |
| INVAInnoviva Inc. | 18.41 | 0.00% | $1.31B | vs PAHC |
Indexes, lists and sector
Phibro Animal Health stock FAQ
What is Phibro Animal Health's stock price today?
PAHC last traded at $33.29 as of Nov 20, 4:00 PM EST, down 2.32% on the day. Prices are delayed at least 15 minutes.
Does Phibro Animal Health pay a dividend?
Yes. Phibro Animal Health pays $0.48 per share annually, a 1.44% yield. The most recent dividend of $0.12 had an ex-dividend date of Nov 25, 2026.
What is PAHC's P/E ratio?
PAHC trades at a trailing P/E ratio of 13.26 and a forward P/E of 8.58.
Who is Phibro Animal Health's CEO?
Mr. Daniel M. Bendheim J.D. is the chief executive officer of Phibro Animal Health Corporation Class A, which has about 2,605 employees.
What is the PAHC 52-week high?
The 52-week high for PAHC is $60.08 and the 52-week low is $28.25. The stock is currently 44.6% below its high.